Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · enGene Therapeutics Inc. (ENGN)

enGene Therapeutics updates July 2026 corporate presentation on detalimogene

Neutral Impact 2 of 5 other Written later

enGene Therapeutics furnished an updated corporate presentation on July 17, 2026, as Exhibit 99.1 to a Form 8-K under Regulation FD. The deck restates the company's pivotal-cohort interim results for detalimogene, its plans for a BLA filing, and cash of $285 million, with no new financial results or guidance stated in the filing.

Key points

  • Pivotal Cohort 1 (N=125, BCG-unresponsive high-risk NMIBC with CIS) shows an any-time complete response rate of 54% (95% CI: 44.9%, 63.0%) in data as of April 21, 2026
  • Pivotal cohort 12-month data and BLA filing are expected in 2H 2026, with potential approval and platform designation in 2027
  • The company cites $285 million in cash expected to fund operations through BLA filing and potential approval

The filing

CompanyenGene Therapeutics Inc. (ENGN)
Form8-K, current report
Filed with the SECJul 17, 2026, 4:05 PM ET
Accession number0001193125-26-307795

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.